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The EphA3 receptor tyrosine kinase preferentially
binds ephrin-A5, a member of the corresponding sub-
family of membrane-associated ligands. Their interac-
tion regulates critical cell communication functions in
normal development and may play a role in neoplasia.
Here we describe a random mutagenesis approach,
which we employed to study the molecular determi-
nants of the EphA3/ephrin-A5 recognition. Selection and
functional characterization of EphA3 point mutants
with impaired ephrin-A5 binding from a yeast expres-
sion library defined three EphA3 surface areas that are
essential for the EphA3/ephrin-A5 interaction. Two of
these map to regions identified previously in the crystal
structure of the homologous EphB2-ephrin-B2 complex
as potential ligand/receptor interfaces. In addition, we
identify a third EphA3/ephrin-A5 interface that falls out-
side the structurally characterized interaction domains.
Functional analysis of EphA3 mutants reveals that all
three Eph/ephrin contact areas are essential for the as-
sembly of signaling-competent, oligomeric receptor-li-
gand complexes.
Eph receptor tyrosine kinases (Ephs)1 are activated through
interaction with cell surface-bound ephrin proteins. Binding
preferences and structural features classify eight type A Ephs
interacting with six type A ephrins that attach to the mem-
brane via glycophosphatidylinositol, as well as six type B Ephs
interacting with corresponding type B transmembrane
ephrins, which contain conserved cytoplasmic domains (1).
Eph/ephrin contacts on opposing cells direct cell movements
underlying developmental patterning events (2, 3) but may also
regulate tumor cell positioning during cancer metastasis and
invasion (4). In many cases Eph signaling results in cytoskel-
etal collapse, down-regulation of cell-cell adhesion proteins,
and cell rounding (2, 5). Concurrent protease-mediated cleav-
age of the Eph/ephrin linkages (6) leads to cell-cell detachment
and repulsion. Interestingly, Eph/ephrin interactions can also
promote cell adhesion, a dichotomy of function that has been
widely recognized (2, 7, 8).
Ephs have a highly conserved domain structure throughout
the animal kingdom (9). The extracellular domain (ECD) con-
sists of a unique N-terminal globular structure, necessary and
sufficient for ephrin binding (10, 11), followed by a cysteine-
rich linker, an EGF-like motif, and two type II fibronectin
domains. For human EphA3 (12), these regions span amino
acid sequence positions 29–203, 204–260, 271–324, 325–435,
and 435–531, respectively. The minimal N-terminal globular
domain has a  jellyroll-like architecture (13), whereas struc-
tures of the cysteine-rich linker and adjoining EGF motif have
not been solved to date.
Clearly, all Eph/ephrin signaling is initiated by a 1:1 inter-
action between the globular Eph domain and a conserved Eph-
binding domain of the ephrins (14). Furthermore, functional
studies have indicated that biological responses rely on oli-
gomerized ephrins to assemble active Eph receptor clusters
capable of triggering downstream signaling cascades (15, 16).
In agreement, the x-ray crystal structure of the complexed
EphB2 and ephrin-B2 interaction domains (17) reveals a 2:2
heterotetramer, containing two types of ligand-receptor con-
tacts of apparent higher affinity (mediating heterodimeriza-
tion) and lower affinity (mediating heterotetramerization).
This configuration of Eph and ephrin domains, where ephrin
and Eph C termini are positioned on opposite sites of a ring-like
planar structure, illustrates how membrane-associated ephrins
and Eph receptors can initiate bi-directional signaling between
adjacent cells (18). However, to date there has been little func-
tional data to validate the Eph/ephrin interaction model pro-
posed in the crystal structure. In addition, the possible contri-
butions of other Eph domains to the active signaling complex
have not been addressed. Interestingly, earlier in vivo studies
indicate a requirement of direct Eph-Eph interaction via the
cysteine-rich motif for Eph function during early development
(11, 17). Although the underlying ephrin-independent Eph
dimerization can trigger trans-phosphorylation in vitro, it is
clear that ephrin-dependent and -independent Eph activation
result in distinct downstream signaling and biological response
pathways (5).
To examine the mechanism of ephrin-A5-induced Eph acti-
vation in more detail, we generated an expression library of
EphA3 ECD point mutants that were selected for proteins of
correct conformation with reduced ephrin-A5 binding. We
found that some 80% of the 50 identified mutants locate to
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EphA3 regions predicted by the EphB2/ephrin-B2 structure to
form part of the Eph/ephrin dimerization and tetramerization
interfaces. Furthermore, kinetic analysis and functional as-
sessment of mutant cell surface-expressed, full-length EphA3
validates the requirement of each of these Eph/ephrin contacts
for the formation of high affinity, biologically relevant EphA3-
ephrin-A5 complexes. Importantly, a distinct third group of
mutants, defining a third Eph/ephrin interface, is positioned
outside the crystallographically characterized ligand-binding
domain, within the cysteine-rich linker previously implicated
in receptor/receptor contacts. Although their kinetics analysis
indicates only moderate effects on ephrin binding, a matching
point mutation in the linker region of cell surface-expressed
EphA3 abrogates ephrin-induced phosphorylation and Crk re-
cruitment, emphasizing the functional importance of this in-
terface. This mutagenesis analysis provides, for the first time,
functional evidence for the essential contribution of several
distinct Eph/ephrin interfaces for the formation of signaling-
competent Eph/ephrin hetero-oligomers.
EXPERIMENTAL PROCEDURES
Expression Constructs and Reagents
EphA3 and Ephrin-A5 Fc Constructs—A cDNA encompassing bp
103–1692 from full-length human EphA3 (12) was cloned into pIgBOS
for expression of the EphA3 exodomain fused to the human IgG1 hinge
and Fc regions (EphA3-Fc), as described (19). EphA3-Fc and ephrin-A5
Fc (gift of Dr. D. Cerretti, Immunex Corp., Seattle, WA) were used for
stable transfection of Chinese hamster ovary cells. Fc fusion proteins
were purified from cell culture supernatants (RPMI 1640, 2.5% immu-
noglobulin-depleted fetal bovine serum) by protein-A-Sepharose (Am-
ersham Biosciences) affinity chromatography, followed by size-exclu-
sion high pressure liquid chromatography.
Yeast EphA3 Expression Construct—A cDNA encoding the EphA3
extracellular domain (Glu21 to Ser539, ECD) was cloned into the yeast
expression vector YEpFLAG-1 (Sigma), containing a FLAG epitope and
the alcohol dehydrogenase promoter for activation of transcription/
translation under low glucose conditions. In addition to a C-terminal
myc epitope (EEQKLISEEDL*), EcoRI and BglII cloning sites were
introduced between the FLAG and Myc sequences to accommodate
insertion of EphA3-ECD cDNAs. Accordingly, the 5-EphA3 oligonu-
cleotide (21ELIPQPSNE30V (12)) was altered to introduce a unique
TABLE I
The effect of divalent cations on PCR mutations in
the EphA3 template
PCR mix MnCl2 MgCl2
Total bases
sequenced
Mutation
rate
mM
A 0 7.0 4440 1:370
B 0.1 7.0 4840 1:345
C 0.25 7.0 6600 1:194
D 0.5 7.0 5566 1:118
E 0 1.5 7380 1:1476
TABLE II
Characteristics of the EphA3 mutant yeast expression library
Approximately 2% of all colonies were estimated to be FLAG-nega-
tive, hence only 94/108 are informative (shown by an asterisk). Replica
filters were screened as described under “Experimental Procedures.”
Myc epitope
present
IIIA4
binding
ephrin A5 Fc
binding
No.
colonies
%
colonies
   45 7
   204 30
   26 4
   308 45
   108 16*
TABLE III
Yeast mutants isolated by expression screening
a Amino acid (AA) residue numbers are in accord with the published sequence (12). The symbols  and  indicate that this site is homologous to
a residue in EphB2, which forms part of the dimerization and tetramerization interfaces, respectively. For double and triple mutant clones (i.e.
containing two or three mutated residues), the second listed positions are highlighted by shading.
b Secondary (2nd) structure elements are assigned according to the EphB2/ephrin-B2 structure (17) (; -sheet).
* These mutants showed weak or marginal IIIA4 antibody binding.
 These residues lie C-terminal to the EphB structure characterized by crystallography (17).
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EcoRI site (Leu22, CTG to Phe, TTC) at the junction of FLAG and
EphA3 sequences, and a BglII sequence was added to the 3-oligonu-
cleotide (corresponding to 534SISGES). A unique BamHI site was fur-
ther created by a silent mutation at nucleotides 997–1002 within the
exon IV-encoded EGF-like domain. The EphA3 protein derived from
this construct was detectable with either anti-FLAG antibody (M2,
Sigma) or the anti-Myc antibody (9E10, generous gift from Dr. D.
Huang, The Walter and Eliza Hall Institute for Medical Research) and
bound ephrin-A5 with comparable affinity to the wild-type receptor.
Random Mutagenesis
Mutants of the EphA3 ECD were created by random mutagenesis
using non-stringent PCR (20). Conditions were optimized to yield 3–4
mutations or 1–3 amino acid changes per clone, so that 500 independent
clones with some 1000 mutated amino acid residues provided a 4-fold
mutational coverage of the target sequence (Table I).
The EcoRI- and BamHI-digested PCR products were ligated into the
EphA3-YEpFLAG-1 vector and the resulting mutant plasmid library,
encoding EphA3 ECD with mutations in the ligand-binding domain and
cysteine-rich linker, and the N-terminal half of the EGF-like domain
(Ala272 to Ser301) was amplified in Escherichia coli. Plasmid cDNAs
from pooled colonies (13,000) were transfected into the Saccharomy-
ces cerevisiae strain BJ3505 containing the plasmid TRP1 gene for
selection in tryptophan-deficient media (SD growth medium). Individ-
ual colonies were seeded into parallel 96-well trays containing selection
medium or normal agar culture medium covered with cellulose nitrate
filters. EphA3 protein expression in colonies was induced by transfer of
the cellulose filters to zero glucose YPEM medium, and secreted pro-
teins were captured by absorption onto 3–4 replicate nitrocellulose
filters for screening. Individual filters from each set of replicates were
probed with monoclonal antibodies (mAbs) against EphA3 (IIIA4), the
Myc epitope (9E10), the FLAG epitope (M2), and with ephrinA5-Fc.
Horseradish peroxidase-conjugated secondary antibodies (Dako) were
used for detection. Colonies showing reduced ephrin-A5 binding were
recovered, and DNA was extracted for sequence analysis of the EphA3
(EcoRI-BamHI) inserts.
Site-directed Mutagenesis and Transient Protein Expression
To deconvolute critical EphA3 ECD clones containing more that one
amino acid change, individual residues were replicated in the pEF
BOS-FLAG-EphA3 mammalian expression vector (11, 14) by site-di-
rected mutagenesis (QuickChange Mutagenesis Kit, Stratagene). Upon
DNA sequence confirmation, mutant and wild-type (w/t) EphA3-pEF
BOS plasmid DNA was transfected into HEK 293T cells (FuGENE 6,
Roche Applied Science), and culture supernatants were harvested after
72 h. EphA3 ECD expression was assessed by Western blot (rabbit
anti-EphA3 antibody (14)) and BIAcore analysis using sensor chips
TABLE IV
Binding characteristics of EphA3 mutants to an
ephrin-A5 sensor surface
 indicates mutants designed by alignment with EphB2/ephrin-B2
structure. * indicates not done (n.d.), lack of IIIA4 binding hindered
purification of assayable protein.
a Position of mutants assigned by alignment with EphB2/ephrin-B2
structure.
b Kinetic properties of mutant proteins binding BIAcore SensorChip-
bound ephrin-A5 or IIIA4 mAb were determined by global analysis
using BIAevaluation software (version 3.2) as described previously (24).
 indicates amino acid positions corresponding to the EphB2/eph-
rin-B2 dimerization interface.
 indicates amino acid positions corresponding to the EphB2/eph-
rin-B2 tetramerization interface.
 indicates amino acid positions outside the EphB2/ephrin-B2 crystal
structure (17).
FIG. 1. Putative molecular model of the complex between the
EphA3 globular domain and ephrin-A5. The atomic coordinates of
the EphB2/ephrin-B2 crystal structure (17) were used to assemble a
model structure of the corresponding EphA3 and ephrin-A5 domains
using MODELLER (version 6) and InsightII software. The model illus-
trates the putative Eph/ephrin dimerization and heterotetramerization
interfaces occupied by ephrin-A5 molecules. For reasons of clarity the
second EphA3 ligand-binding domain of the tetrameric complex is omit-
ted. The bottom panel represents a 180o rotated view of the complex.
The carbon backbone of ephrin-A5 molecules is displayed as tube dia-
gram and the EphA3 ligand-binding domain represented as space-
filling atomic model. EphA3 residues are color-coded according to their
predicted proximity to Eph/ephrin interaction sites: yellow (4 Å), green
(6 Å), blue (8 Å), and gray (8 Å). Altered residues of EphA3 mutants
that have been analyzed by kinetic BIAcore analysis (Table IV) are
marked by red shading and also by their corresponding amino acid
position within the EphA3 sequence.
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containing ephrin-A5 and IIIA4 on parallel flow channels. All proteins
used for kinetic analysis were purified by IIIA4 affinity chromatogra-
phy (21). The proteins were analyzed by SDS-PAGE/silver staining and
Western blot using -EphA3 (polyclonal) or -FLAG (monoclonal) anti-
bodies. Western blots were developed using ECL detection (SuperSignal
Chemiluminescence, Pierce).
BIAcore Analysis
Purified EphA3 ECD proteins in BIAcore buffer (10 mM Hepes, pH
7.4, 0.15 M NaCl, 3.4 mM EDTA, 0.005% Tween 20) were analyzed at
27 °C on parallel IIIA4 and ephrinA5-derivatized CM5 sensor chips
(BIAcore 2000 optical biosensor, BIAcore AB, Sweden). The protein
concentrations were determined at A215 (21). To ascertain the perform-
ance of sensor chip-immobilized proteins, samples of purified EphA3
ECD (62.5–1000 ng/ml) were analyzed in each assay. Interaction kinet-
ics was evaluated from eight serial dilutions of each sample by Global
Analysis using the BIAevaluation software (version 3.1).
Alexa FluorTM 546 EphrinA5-Fc Conjugate and
Confocal Microscopy
Purified ephrinA5-Fc was labeled using an Alexa FluorTM 546 fluo-
rescent labeling kit (Molecular Probes). Coupling of the ALEXA dye and
its effect on the biological integrity of ephrin was monitored during the
labeling reaction by spectral (high pressure liquid chromatography
diode array detection) and BIAcore analysis, respectively. Labeling
reactions were terminated when the first decrease in binding was
detected. Ephrin binding in situ to cells transiently transfected with
mutant EphA3-GFP receptors was analyzed by 10 min of incubation
with 1.5 g/ml, human IgG pre-clustered Alexa 546 ephrinA5-Fc. The
cells were washed with ice-cold phosphate-buffered saline, fixed using
4% paraformaldehyde, and mounted in distyrene/plasticiser/xylene.
Confocal fluorescence microscopy using an Olympus FV500 with an oil
immersion objective provided the resulting images.
Modeling of EphA3 Structure
A three-dimensional model of the human EphA3 ligand-binding do-
main complexed to ephrin-A5 was based on the x-ray crystal coordi-
nates of the corresponding mouse EphB2-ephrin-B2 complex (17), (Pro-
tein Data Bank code 1KGY). The human EphA3 sequence and the
published sequence alignment (17) (identical EphB2/EphA3 residues
are indicated with “.”) are as follows:
hEphA3:EVNLLDSKTIQGELGWISYPSHGWEEISGVDEHYTPIRTYQVCNVMDHS
mEphB2:.ET.M..T.ATA....MVH.PS....V..Y..NMNT.........FES.
hEphA3:QNNWLRTNWVPRNSAQKIYVELKFTLRDCNSIPLVLGTCKETFNLYYME
mEphB2:.......KFIR.RG.HR.H..M..SV...S...S.P.S.........Y.
hEphA3:SDDDHGVK----FREHQFTKIDTIAADESFTQMDLGDRILKLNTEIREV
mEphB2:A.F.LAT.TFPNWM.NPWV.V.........S.V...G.VM.I...V.SF
hEphA3:GPVNKKGFYLAFQDVGACVALVSVRVYFK
mEphB2:...SRN........Y.G.MS.IA...FYR
mEphrinB2:---IVLEPIYWNSSNSKFLPGGGLVLYPQIGDKLDIICPKVDSKT-VGQY
hEphrinA3:KAVADRYAV......PR.QR-.DYHIDVC.N.Y..VF..HYEDSVPEDKT
mEphrinB2:EYYKVYMVDKDQADRCTIKKENTPLLNCARPDQ---DVKFTIKFQEFSPN
hEphrinA3:.R.VL...NF.GYSA.DHTSKGFKRWE.N..HSPNGPL..SE...LFTPF
mEphrinB2:LWGLEFQKNKDYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVG-
hEphrinA3:SL.F..RPGRE.FY..SAIPDNGRRS------CLKLKVFVRPTNSC
These were used to create 200 models of the ephrin-A5 complexed
EphA3 ligand-binding domain using MODELLER (release 6) (22) (Ac-
celrys, San Diego). The models were evaluated for structural quality
and compatibility with known protein structures as described (23) using
the “ProStat” and “Profiles3D” modules of InsightII (Accelrys, San
Diego).
RESULTS
Library of EphA3 Variants Deficient in EphrinA5 Binding—
Our mutagenesis approach targeted an 830-bp EphA3 cDNA
fragment spanning the globular ligand binding, the cysteine-
rich linker, and the N-terminal part of the EGF-like domain.
During optimization we confirmed by sequence analysis of ran-
domly selected bacterial colonies the following: (a) all 4 bases
were mutated with similar frequencies; (b) there was no appar-
ent restriction in nucleotide placement; and (c) mutants were
randomly distributed across the entire sequence. This strategy
yielded 1300 bacterial YEpFLAG-1 colonies and a derived ex-
pression library of 700 mutant yeast clones. As early results
indicated less than 2% of FLAG-negative clones (empty vector
or lack of secretion), routine screening for the FLAG epitope
was discontinued to preserve samples. The analysis of 677
informative colonies suggests that 50% of the clones produced
proteins with apparent defects in ephrin-A5 binding (Table II).
To evaluate whether any mutations disrupt the overall protein
fold, we used the IIIA4 anti-EphA3 mAb that has been used
previously to monitor the EphA3 conformation (21). This mAb
binds only to the properly folded N-terminal globular domain of
the receptor (11). The 14% Myc-negative mutants were ex-
cluded from further analyses as they likely represent prema-
turely terminated translation products. Of the remaining col-
FIG. 2. Ephrin-A5 binding properties of soluble EphA3 and
derived point mutants. a, the binding curves of non-mutated EphA3
extracellular domain (w/t EphA3) and derived point mutants as indi-
cated by amino acid position are illustrated. Binding of the purified
proteins was examined (Table IV) by applying serially diluted EphA3
proteins to monovalent ephrin-A5 and a non-relevant control protein
(insulin) immobilized on parallel channels of the BIAcore sensor chip
surface. The illustrated relative response units (RU) represent binding
data of EphA3 protein samples at 30 nM that were corrected for sample-
related bulk refractive index changes by subtraction of responses mon-
itored on the control surface. b, assessment of protein integrity and
purity of mutant EphA3 by Western blot and silver staining. The
soluble, non-mutated EphA3 extracellular domain (w/t) or selected mu-
tants, as indicated, were affinity-purified from cell culture superna-
tants (sn). The affinity column eluates (lanes 1 and 2) together with
crude supernatants, including those lacking IIIA4 immunoreactivity
(D130G, V231D, and V133G), and purified soluble EphA3 (14) were
analyzed by anti-FLAG and anti-EphA3 Western blots. Samples from
the affinity column eluates were analyzed by silver staining (bottom
panel). This figure illustrates the analysis for only a small selection of
mutant proteins as representative examples.
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onies, 334 (57%) retained ephrin-A5 binding, only 26 of which
lost immunoreactivity to IIIA4. The majority (79%) of mutants
that failed to bind ephrin-A5 also did not bind IIIA4. Only 7%
of all mutants lost ephrin-A5 binding capacity while retaining
IIIA4 reactivity and were selected for further detailed analysis.
Sequence Analysis Reveals Three Distinct Mutant Clusters
Depicting EphA3/Ephrin-A5 Interaction Sites—cDNAs from 38
of the 45 EphA3 clones with compromised ephrin-A5 binding
were recovered for sequence analysis. Although the selection of
mutants focused on clones binding IIIA4 (Table II), some of
these were found to exhibit substantially reduced or marginal
IIIA4 reactivity in subsequent assays (indicated by *, Table III,
see also Table IV). In a single case, a clone initially negative for
ephrin-A5 binding revealed w/t binding characteristics in sub-
sequent assays (Glu60 3 Asp). In total, sequence analysis re-
vealed 51 single amino acid substitutions in the 38 clones,
accounting for the incidence of double (16) and triple mutations
(1) in several clones (Table III). These mutants are listed in the
context of secondary structure elements of the corresponding
EphB2 crystal structure, and their position within the EphB2/
ephrin-B2 heterodimerization () or heterotetramerization ()
interfaces (17) is indicated. As expected, the majority of these
(40/51) affects residues that fall within the ligand-binding do-
main (residues 29–207), and 72.5% (29/40) of these involve
residues that are involved in receptor/ligand contacts in the
EphB2/ephrin-B2 crystal structure (17). It should be noted that
EphA3 residues 150–152 do not have direct EphB2 counter-
parts but that inspection of the crystal structure reveals their
position in the back of the ligand-binding channel (see Fig. 1).
Importantly, 8 EphA3 mutants with reduced ephrin-A5 bind-
ing capacity map to the cysteine-rich linker region of EphA3
(11), which falls outside the ephrin-binding domain elucidated
in the corresponding EphB2 crystal structure (17).
Homology Model of the EphA3-Ephrin-A5 Complex—Based
on significant sequence identities between EphB2 and EphA3
ligand-binding domains (56% identity) and between ephrin-B2
and ephrin-A5 receptor-binding domains (30% identity), we
modeled a putative EphA3-ephrin-A5 complex by using the
coordinates of the EphB2/ephrin-B2 crystal structure as basis
(Fig. 1). The proximity of critical EphA3 residues identified by
mutagenesis to the bound ephrin is indicated by yellow (4 Å),
green (6 Å), and blue (8 Å) coloring, respectively. The positions
of the ephrin-A5-binding mutants within this three-dimen-
sional model (indicated by red transparent shading and yellow
numbering) are concentrated around regions of receptor-ligand
contact. Two spatially distinct mutant clusters broadly mirror
the ligand-interaction interfaces defined in the EphB2/eph-
rin-B2 crystal structure (17). Most mutants are in residues
belonging to the high affinity dimerization interface, including
the B-C and C-D loops (Table III, His503 Gln and
Glu533 Lys), the D and E strands (Table III, Val583 Ala and
Asp753 Val), the ligand binding groove (Table III,
Thr1023 Ala and Phe1523 Leu), its base (Table IV,
Glu1503 Gly and Ser1513 Gly), and the G-H loop forming the
“lid” of the groove (Table III, Ser1083 Gly, Ile1093 Thr, and
Leu1113 Phe). Several mutants fall within the Eph/ephrin
heterotetramerization interface (Table III, Ser913 Ala,
Gly1323 Glu, Val1333 Glu, and Lys2003 Ile), confirming the
validity of the tetrameric Eph/ephrin model. In addition to the
mutants within the crystallographically characterized do-
mains, three others, which also affected ligand binding
(Asn2083 Lys, Met2183 Lys, and Asn2323 Ile), map to the
cysteine-rich linker region that connects onto the EGF-like
putative receptor-receptor dimerization domain (11).
Kinetic Binding Analysis Distinguishes Three EphA3/Eph-
rin-A5 Contact Surfaces—From the 51 identified amino acid
substitutions, a representative group of 26 mutants contained
within or on the back of protein domains with predicted ephrin
contacts (Fig. 1), as well as mutants outside the domains de-
scribed in the model structure, were selected for preparation of
mutant EphA3 cDNA for transient expression in HEK 293 cells
(Table IV). Although 24 of these yielded proteins suitable for
IIIA4 affinity isolation and ephrin-A5 binding analysis by sur-
face plasmon resonance (Fig. 2 and Table IV), two of the listed
amino acid substitutions disrupted IIIA4 binding and hindered
affinity isolation (Table IV, not done). In addition, three EphA3
point mutants, assigned through alignment to matching
EphB2/ephrin-B2 contact surfaces (indicated by ¥ in Table IV)
were examined in parallel.
We examined the kinetic properties of mutant, in comparison
TABLE V
Binding of ephrin-A5 or ephrin-B2 to sensor surfaces containing EphA3(Val133 3 Glu),
EphA3(Phe152 3 Leu) and EphA3 (Val133, Phe152) mutants
Analyzed ephrin proteina Immobilized EphA3 proteinb ka
c kd
c KD
c
1/ms 1/s nM
EphrinA5 w/t 6.2  105 0.006 9.6
Val133 3 Glu 7.9  105 0.02 25.8
Phe152 3 Leu 2.4  105 0.26 1070
Val133, Phe152 1.5  105 0.229 1580
EphrinB2 w/t Below BIAcore range
Val133 3 Glu Below BIAcore range
Phe152 3 Leu Below BIAcore range
Val133, Phe152 Below BIAcore range
EphrinA5-Fc w/t 3.4  105 4.0  105 0.1
Val133 3 Glu 4.3  105 3.0  104 0.7
Phe152 3 Leu 3.8  105 0.002 5.6
Val133, Phe152 3.7  105 0.003 7.4
EphrinB2-Fc w/t 1.0  104 0.00026 27.1
Val133 3 Glu 4.2  104 0.0016 35
Phe152 3 Leu 7.4  104 0.00306 41.2
Val133, Phe152 3.2  104 0.00174 54.2
a Soluble ephrins or ephrin-Fc fusion proteins were produced and purified as described previously (14, 17). Serial dilutions between 1 M and 7.8
nM (monovalent ephrin) and 24 and 0.19 nM (divalent ephrin) were injected across parallel SensorChip surfaces as described under “Experimental
Procedures.”
b Points mutations of EphA3 dimerization and tetramerization domains were introduced into the pIG-EphA3 expression vector by site-directed
mutagenesis. Resultant w/t and mutant proteins, purified to homogeneity were immobilized onto parallel channels of BIAcore sensorchips for
analysis of ephrin binding.
c Kinetic characteristics of BIAcore SensorChip-bound, w/t, and mutant EphA3 Fc binding soluble ephrin were determined by global analysis
using BIAevaluation software (version 3.2) as described previously (24).
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to w/t EphA3 ECD proteins, by estimating apparent binding
affinities to ephrin-A5 from association and dissociation rate
constants, observed in a series of parallel BIAcore experiments.
In agreement with earlier studies, Chinese hamster ovary cell-
derived FLAG-tagged w/t EphA3, bound sensor chip-coupled
ephrin-A5 with comparable affinity (11) (KD, 58 nM) to the
unmodified, HEK 293 cell-derived EphA3 exodomain (KD, 86
nM). As expected, amino acid substitutions within the predicted
Eph/ephrin dimerization and tetramerization interfaces
resulted in reduction or loss of ephrin-A5 binding. Overall,
mutations within the putative ephrin binding groove and di-
rectly exposed to ephrin (see Fig. 1) had the most severe effects,
and in several cases (Table IV, Thr1023 Ala, Arg1043 Gln,
Gln150 3 Gly, Phe1523 Leu) their affinities were below the
BIAcore measuring range (Fig. 2a). Interestingly, a change in
side chain size at Thr102 3 Gln affects ephrin binding some
150-fold less than the introduction of an aliphatic side chain
(Thr102 3 Ala) at this position. In addition, mutations
Ser1083 Gln, Ile1093 Thr, and Leu1113 Phe within the EphA3
G-H loop, forming the lid of the corresponding EphB2 ligand
binding groove, greatly affected ephrin binding (Table IV).
Amino acid substitutions of residues within the H-I loop,
previously shown as part of the “low affinity” tetramerization
domain (17) (Asp130 3 Gly, His131 3 Glu, Gly132 3 Glu, and
Val133 3 Glu), also impacted significantly on ephrin-A5 bind-
ing but less dramatically than the dimerization site mutants.
By comparison, replacement of Gly132 and Val133, residues
immediately adjacent to the 4-residue alignment gap that is
thought to determine Eph subclass specificity (17), had the
most notable effects (Table IV).
Interestingly, replacement of Asn2083 Lys, Met2183 Lys,
Met2183 Ile, and Asn2333 Ile, positioned in the cysteine-rich
linker region outside the crystallographically characterized do-
main affected ligand binding significantly (3–5-fold, Table IV),
but again to a lesser degree than mutations within the ligand
binding groove.
Multivalent Ephrin-A5 Binding to Surface-tethered EphA3
Mutants—We next compared the binding of monovalent or
divalent ephrins to sensor chip-tethered EphA3 mutants be-
cause divalent ephrin Fc derivatives, with the inherent capac-
ity of docking to two distinct ligand binding interfaces simul-
taneously, are commonly used to study Eph function in vivo.
w/t EphA3 ECD and mutants with substitutions either within
the heterodimerization site (EphA3-Phe152 3 Leu) and the
heterotetramerization site (EphA3-Val133 3 Glu) or mutated
in both sites simultaneously (EphA3-Phe152,Val133) were im-
mobilized on parallel BIAcore sensor surfaces. In agreement
with the results presented above, mutation of EphA3-Phe152
dramatically reduced ephrin-A5 binding (111-fold, Table V). By
comparison, substitution of EphA3-Val133 affected ephrin-A5
binding only 3-fold, and as a double mutant together with the
Phe152 replacement, yielded a further 1.5-fold decrease of its
binding affinity (Table V and Fig. 3a). Reduced binding affinity
of mutant EphA3 seemed primarily due to increased dissocia-
tion rates, whereas a marginal effect on the association rate of
the double mutant was noted. As expected, the binding of
monovalent ephrin-B2, performed in a parallel control experi-
ment, was below the BIAcore working range.
In agreement with previous studies (14) the interaction of
divalent ephrin-A5 Fc revealed increased avidity (reduced off-
rates), yielding an apparent affinity for w/t EphA3 of KD of 0.1
nM. Binding of ephrin-A5 Fc, but not that of ephrin-B2 Fc
analyzed in parallel, was increasingly perturbed by point mu-
tants in the heterotetramerization and heterodimerization
sites and mutation of both sites together (Table V and Fig. 3b).
EphA3 (Phe152 3 Leu) showed a 56-fold reduced affinity (KD,
5.6 nM), although the additional mutation at Val133 increased
this effect only moderately (EphA3-Val133, Phe152, KD, 7.4 nM).
Interestingly, a nanomolar affinity maintained by the single
and double mutants in this experimental setting suggests that
residual ligand binding contacts of EphA3 contribute signifi-
cantly to the overall interaction.
We also assessed the notion that mutation of EphA3 within
the putative “specificity loop” (13) may affect the binding ca-
pacity of other EphA3-binding ephrins (14) differently to eph-
rin-A5 Fc. However, BIAcore responses of ephrin-A1 Fc, eph-
rin-A3 Fc, ephrin-A4 Fc, ephrin-A5 Fc, and ephrin-B2 Fc at
equimolar (7.5 nM) concentrations were equally reduced (59–
74%), suggesting that this single residue substitution has little
effect on the suggested specificity-determining role (13) of this
protein loop.
The IIIA4 mAb Binds to a Site Closely Adjacent but Not
Overlapping the EphA3 Tetramerization Interface—Detailed
binding analysis revealed that several EphA3 amino acid sub-
stitutions severely affected or abrogated binding of the IIIA4
mAb (Table IV). In particular mutants clustering within the
tetramerization interface (Asp130 3 Gly, Gly132 3 Glu, and
FIG. 3. Effect of high and low affinity binding site mutations
on ephrin binding characteristics of EphA3. Parallel channels of
BIAcore sensor chips were derivatized with either w/t EphA3, mutant
EphA3Val1333Glu (tetramerization site mutant), EphA3Phe1523 Leu
(dimerization site mutant) or EphA3Phe152,Val133 (double mutant), and
binding of monovalent ephrin-A5 (a) or divalent ephrin-A5 Fc (b) was
monitored to determine kinetic parameters (Table V). Relative and
corrected responses of 200 nM monovalent ephrin-A5 or 24 nM eph-
rin-A5 Fc binding are illustrated in the figures. c, comparison of the
binding of various ephrin-Fc fusion proteins to w/t or Val133 3 Glu
mutant EphA3. Binding of ephrin-Fc fusion proteins, as indicated, or
recombinant human Fc (25 nM) was analyzed on parallel channels of a
BIAcore sensor chip derivatized with either the w/t (light blue) or
mutant (Val1333 Glu, red) EphA3 extracellular domain. The binding of
human Fc domain at an equal concentration was used as a control in
this experiment. The loss of binding due to the Val133 3 Glu mutation
is indicated (% of w/t response).
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Val133 3 Glu) revealed significantly reduced IIIA4 binding,
suggesting neighboring or overlapping binding sites of IIIA4
and of ephrin-A5. To address this, we examined whether sat-
uration of IIIA4-binding sites would affect the binding of eph-
rinA5-Fc to an EphA3-coated sensor chip (Fig. 4). Comparing
the binding of ephrin-A5 Fc to EphA3 sensor chip surfaces
previously exposed to buffer (Fig. 4A) or IIIA4 (Fig. 4C) sug-
gests a marginally reduced amount of bound ephrin-A5, due to
a small apparent increase in the ephrin-A5 dissociation rate
from IIIA4-loaded EphA3 (Fig. 4C). Exposure of the EphA3
surface with an isotype matched, non-relevant control anti-
body, tested in a parallel control experiment, did not change
the binding characteristics of ephrin-A5 Fc (Fig. 4B). Interest-
ingly, we could not detect an effect of IIIA4 binding on the
interaction with monovalent ephrin-A5 (data not shown), sug-
gesting that the dominating contribution from the high affinity
binding site would mask detection of reduced binding at the low
affinity binding site.
Both the Low and High Affinity Ephrin-binding Sites in
EphA3 Are Essential for a Biological Response—To assess the
functional relevance of selected ephrin-binding mutants, we
tested their ability to trigger signaling of cell surface-expressed
EphA3. To monitor ephrin-A5 binding to HEK 293 cell surface-
expressed w/t and mutant EphA3, we introduced the single
residue, Phe152 3 Leu, and the double residue, Val133 3 Glu,
Phe152 3 Leu mutation into full-length EphA3 containing a
C-terminal GFP (green fluorescence). Transfection of HEK 293
cells with corresponding expression constructs revealed abun-
dant cell membrane as well as cytoplasmic expression of the
GFP-tagged receptor constructs (green fluorescence, Fig. 5a). To
monitor ligand binding, we attached Alexa 546 to ephrin-A5 Fc
(red fluorescence). Results summarized in Fig. 5 confirm avid
Alexa 546-ephrin-A5 Fc binding to w/t EphA3, or to the 3xYF
EphA3 mutant, lacking juxtamembrane and activation loop
tyrosines (5) and used as control (see below). Merged images of
green and red fluorescent micrographs indicate prominent
areas of the fluorescent proteins at the cell membrane (merged
yellow image), as well as co-localized cytoplasmic patches
(yellow) of ephrin-A5 Fc (red) and EphA3 (green) fluorescence,
suggesting internalization of GFP-EphA3/Alexa 546-ephrin-A5
Fc complexes. In agreement with the findings from kinetic
experiments, cells expressing EphA3-Phe152 3 Leu as well as
EphA3-Phe152,Val133 expressing cells, reveal greatly reduced,
ephrin-A5 Fc binding.
We next studied the effect of ephrin-A5 binding mutations on
EphA3 signaling by immunoprecipitation analysis of w/t or
mutant EphA3-transfected HEK 293 cell lysates, using EphA3
phosphorylation and CrkII recruitment as essential criteria for
EphA3-directed cellular responses (5). Mutations within the
dimerization (Phe152 3 Leu) and tetramerization (Val133 3
Glu) domains reduced ephrin-A5-mediated trans-phosphoryla-
tion and CrkII recruitment (Fig. 5f) to levels below those re-
corded with signaling-deficient 3xYF EphA3, lacking the essen-
tial autophosphorylation sites (5). Importantly, the Asn232 3
Ile mutation within the cysteine-rich hinge region also results
in marginal EphA3 phosphorylation and CrkII recruitment,
emphasizing the functional importance of this newly identified
binding interface.
Together our experiments indicate that although EphA3 mu-
tants with single residue substitutions in the heterodimeriza-
tion or tetramerization sites, or in the cysteine-rich hinge re-
gion, all maintain residual ephrin-A5 binding capacity, an
Eph-ephrin complex with all three sites intact is essential for
EphA3 activation and downstream signaling.
DISCUSSION
A Novel Mutagenesis Approach for Structure/Function Anal-
ysis—We describe a novel mutagenesis strategy that allowed
us to identify Eph receptor surfaces that are essential for
ephrin binding and the initiation of Eph receptor signaling.
Our approach is based on isolation of ephrin binding-compro-
mised proteins from a library of random EphA3 point mutants
that cover receptor domains implicated in ephrin binding and
the initiation of biological responses (10, 11). Analyzing se-
creted mutant proteins during the primary colony screen, both
functionally (for compromised ephrin-A5 binding) and immu-
nologically (for native conformation), allowed an immediate
and efficient selection of receptor mutants (7%) with altered
ligand interaction sites and exclusion of those with a more
global disruption of their overall domain structure. Effective
FIG. 4. Consecutive binding of the IIIA4 -EphA3 mAb and ephrin-A5 to SensorChip-tethered EphA3. To test if ephrin-A5 and the
IIIA4 mAb can bind simultaneously to EphA3, solutions (in BIAcore buffer) of IIIA4 (C, D, and F, 200 nM), anti-Myc 9E10 mAb used as control (B
and G, 200 nM), or buffer (A) were injected onto an EphA3-derivatised sensor surface (indicated as11). Following this injection of IIIA4 (or control
antibody, 9E10) a subsequent injection (marked 12) of ephrin-A5 Fc (A–C, 25 nM) or a control protein (ephrin-B2 Fc, D) was introduced onto the
same sensor surface. We confirmed in a control experiment that the first IIIA4 mAb injection (200 nM) indeed saturated the antibody binding
capacity of the EphA3 sensor surface. To do this a second IIIA4 injection (E and F, 200 nM) was applied onto the sensor surfaces that had previously
reacted with 100 nM (E) or 200 nM (F) IIIA4 mAb (inset). In the figure, the relative response levels of control samples A and B during the first
injection cycle were adjusted to match the response level of the sensorgrams C and D in the second injection cycle.
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FIG. 5. Val133 3 Glu and Phe152 3
Leu mutations affect ephrin-A5 bind-
ing, receptor phosphorylation, and
CrkII recruitment in EphA3 express-
ing HEK 293T cells. HEK 293T cells
transiently transfected with chimeric pro-
teins of GFP fused to the C terminus of
non-mutated EphA3 (a), EphA3-Phe1523
Leu (b), EphA3Val133 3 Glu (c),
EphA3Val133/Phe152 (d), or EphA3-
Tyr596,602,7793 Phe (5) (e) used as control
were exposed (10 min) to Alexa-labeled
ephrin-A5 Fc, and non-bound ephrin-A5
Fc was removed by washing (phosphate-
buffered saline) prior to fixation and mi-
croscopy. Images of GFP fluorescence
(green, a–e), Alexa 546 fluorescence (red,
a–e), and merged images (yellow, a–e)
of GFP and Alexa 546 fluorescence are
shown. Fluorescence signals inside the
cells represent cytosolic pools of GFP-
EphA3 (green) as well as internalized Al-
exa-labeled ephrin-A5 Fc (red) complexed
to GFP-EphA3. f, anti-phosphotyrosine
and anti-Crk immunoprecipitates from
Triton X-100 lysates of HEK 293 cells
transfected with w/t or mutant EphA3 or
with a vector control (as indicated) were
stimulated with pre-clustered ephrinA5-Fc
and analyzed by Western blot (WB) with
anti-EphA3 antibodies. To assess even
loading, parallel samples from the same
lysates were immunoprecipitated (IP)
with IIIA4 anti-EphA3. In parallel control
samples, immunoblot analysis was per-
formed with cells expressing EphA3-
Tyr596,602,7793 Phe, mutated at the prin-
ciple auto-phosphorylation sites and
yielding marginal levels of EphA3 phos-
phorylation and CrkII recruitment (5).
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isolation of mutants with intact global protein architecture
was facilitated largely by selecting mutant proteins through
their capacity of binding IIIA4, a mAb previously used suc-
cessfully to monitor the biological integrity of recombinant
EphA3 (21). Sequencing of 84% (38/45) of the clones recovered
from this screen revealed, either by alignment to known
EphB2/ephrin-B2 interaction surfaces or by functional assay,
that in 37/38 cases at least one of the mutated amino acids is
either directly involved with or falls within the immediate
vicinity of predicted Eph/ephrin contacts (Table III). It is of
note that in double mutant yeast colonies, loss of ephrin
binding was generally due to one severe mutation within and
a less disruptive mutation on the margin or outside a high
affinity binding domain (Table IV). Overall, the integration of
library screen and detailed kinetic analysis allowed us to
accurately pinpoint essential ephrin contact points on the
EphA3 ECD. Although previous structure/function studies
(10, 11) and crystallography (18) already offered important
insights into the molecular architecture of Eph-ephrin com-
plexes, the receptor mutants described here provide the first
available reagents to test the predictions drawn from these
studies. We believe that the success of this strategy to reli-
ably identify protein/protein interaction surfaces suggests its
general applicability for the study of other receptor/ligand
systems.
Functional Mutant Analysis Defines Three Distinct Ephrin
Interaction Surfaces—Bi-directional Eph/ephrin signaling be-
tween opposing cells is facilitated by multimeric receptor-li-
gand complexes, and elucidation of the EphB2/ephrin-B2 crys-
tal structure (17) allowed detailed predictions of the protein
interfaces that are essential for the formation of an active
signaling complex (18). The proposed heterotetrameric ring-
like model structure, held together by two distinct (low and
high surface area) contact surfaces that position the Eph and
ephrin C termini to opposite sites of the crystal plane, provides
a structural basis for the requirement of higher order Eph-
ephrin complexes to initiate bi-directional signals. However, to
date there was no functional data to confirm the requirement of
two distinct Eph/ephrin contact sites for Eph/ephrin signaling.
We now provide, for the first time, evidence for the functional
relevance of these two distinct interfaces, both for high affinity
ephrin binding and for the initiation of Eph downstream sig-
FIG. 6. Model of ephrin-induced
Eph clustering. Monomeric Ephs and
ephrins (A) combine into dimeric or tet-
rameric complexes; high affinity Eph/eph-
rin dimers (14) (B) assemble via a lower
affinity interface into Eph/ephrin het-
erotetramers (17) (B). Functional studies
(15) demonstrated a requirement for
cross-linking (via anti-Fc antibodies, yel-
low fork) of dimeric ephrins-Fc fusion pro-
teins (red) to trigger Eph signaling and
biological responses (C). In vivo, mem-
brane-bound ephrin can engage in addi-
tional Eph contacts to facilitate the for-
mation of higher order Eph/ephrin
signaling clusters. A candidate interface
for these contacts is the third binding site
between ligand binding and cysteine-rich
domains, now identified in our mutagen-
esis study (D). We hypothesize that liga-
tion at this interface (7) triggers the for-
mation of Eph/Eph contacts through the
cysteine-rich domain (8), an interaction
that has documented importance for Eph
signaling (11) (E). These low affinity in-
teractions are notable in vitro only with
pre-clustered ephrins and in vivo would
require a critical ephrin density on the
cell membrane. We postulate that the
cluster of Eph/ephrin tetramers is suffi-
cient as nucleus for “cluster polymeriza-
tion” (F). The final size of the cluster thus
would depend on the local Eph and ephrin
density.
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naling. Alignment of the isolated mutants onto a putative
EphA3/ephrin-A5 structure (Fig. 1) confirms two clusters posi-
tioned within or in the immediate vicinity of the extensive
dimerization domain and the smaller tetramerization
interface.
A first group of mutant residues that cluster within or
around the proposed ephrin binding groove of the dimerization
domain (Glu413 Arg, His503 Gln, Glu533 Lys, Val583 Ala,
Thr102 3 Ala, Arg104 3 Glu, Ser108 3 Gly, Ile109 3 Thr, and
Phe152 3 Leu, Tables III and IV), and which are involved in
Van der Waals and intermolecular hydrogen bonds in the cor-
responding EphB2-ephrin-B2 complex, essentially ablate bind-
ing of monovalent ephrin. Thus, single amino acid substitu-
tions within the high affinity binding region of EphA3 (Table
IV) reduce binding to ephrin-A5 surfaces to background levels,
suggesting that other ephrin binding interfaces on their own
are insufficient to mediate effective one-to-one contacts. Inter-
estingly, we observe marginal binding of monovalent but sig-
nificant binding of divalent ephrin-A5 Fc to a mutant EphA3-
Phe1523 Leu sensor surface (Table V), the latter representing
practically a “high density array” of different ephrin interaction
sites. Although differences in accessibility of interaction sites of
immobilized ephrin-A5 or EphA3 could account for this con-
trasting kinetic behavior, increased avidity of divalent eph-
rin-A5 Fc, in particular to bind to several possible sites on this
“array,” may also contribute to increased binding. It is of note
in this context that, inherent to our BIAcore analysis, kinetic
properties are derived from the interacting behavior of associ-
ated components in situ rather than from their condition at
thermodynamic equilibrium.
A second cluster of mutants, mapping to the proposed
tetramerization site of the model structure, reveals affinity
changes that are orders of magnitude smaller than those of
mutations within the high affinity groove. The quantitation
of “mutant severity” by kinetic binding analysis seems to
correlate with the contribution of corresponding w/t residues
to the structural stability of the predicted complex. In this
latter case, significant binding of (tetramerization site) mu-
tant receptor to sensor surface-tethered ephrin (Table IV)
suggests a dominating contribution of the high affinity
dimerization interface to the overall interaction. Impor-
tantly, placement of representative mutants from either the
dimerization or the tetramerization interface into cell sur-
face-expressed, full-length EphA3 dramatically reduces
trans-phosphorylation and initiation of downstream signal-
ing (Fig. 5f), demonstrating the requirement of both interac-
tions for an active signaling complex.
Finally, and most importantly, a distinct group of mutants
identified in our screen, including Asn2083 Lys, Leu2093 Gln,
Met218 3 Lys, Val231 3 Asp, Asn232 3 Ile, and Ser245 3 Arg,
delineate a novel Eph/ephrin interaction interface within the
cysteine-rich hinge region that has not been characterized
within the EphB2/ephrin-B2 crystal structure. These mutants
cluster within two short sequence motifs Asn208 to Ala210 and
Val231 to Ser235 that are conserved in human, mouse, chicken,
and zebrafish EphA3, EphA4, and EphA5 but not in other Eph
proteins. It is of note that these three Eph receptors share a
highly conserved and well described ephrin-A5-dependent,
axon guidance function during development of the visual sys-
tem (3). While overall, the ephrin binding capacity of these
mutants is less affected than that of the previously described
ones, marginal signaling in Val231 3 Asp EphA3 clearly em-
phasizes the importance of this interface for the formation of
biologically active EphA-ephrin complexes.
Proposed Mechanisms That Assemble Active Eph-Ephrin
Signaling Complexes—By taking the findings from the cur-
rent study and from the molecular architecture of the EphB2-
ephrin-B2 complex (18) into consideration, we suggest that
ephrin-induced EphA3 clustering into active signaling com-
plexes involves at least three distinct binding interfaces (Fig.
6). A 1:1 interaction of monovalent, soluble ephrin with
EphA3 is facilitated primarily through docking to the high
affinity binding groove, whereas binding of soluble, monova-
lent ligand to the low affinity domains (i.e. as the predicted
residual ephrin-A5 binding to a high affinity binding site
mutant) is not detected in our experiments. The two binding
interfaces within the crystallized ephrin-binding domain are
positioned in a manner that a single ephrin cannot engage in
both sites simultaneously, a feature that emphasizes the
necessity of dimeric (e.g. Fc-tethered) or multimeric ligands
to enable the assembly of Ephs into tetrameric, or possibly
higher order, signaling complexes (18). Experimental evi-
dence further demonstrates that clustering of Fc-tethered
ligands is essential for activation of downstream signaling
and biological responses, thus implying the formation of
higher order clusters (15). The third ephrin interaction site
outside the globular ligand-binding domain is a likely candi-
date for the Eph structure that participates in this clustering
mechanism. The position of this interface as linker between
the previously defined ephrin binding (17) and Eph-Eph
dimerization domains (11) invokes the intriguing possibility
that ephrin docking to this site induces an orientation of
receptors that leads to aggregation into larger Eph/ephrin
signaling clusters (Fig. 6E). In line with this hypothesis,
previous studies indicated that EphA3/EphA3 contacts via
the EGF-like domain can facilitate Eph phosphorylation and
are essential for receptor function (11). In ongoing experi-
ments we are now using the Eph receptor mutants discussed
in this study to examine the mechanisms of ephrin-independ-
ent EphA3 dimerization.
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